This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
News & Press: Opportunities for Participation

Pfizer Global Medical Grants Announces a Research RFP in Hemophilia

Friday, May 17, 2019   (0 Comments)
Posted by: Andy Masten
Share |

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an external review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program.

 

Date RFP Issued: February 22, 2019

Geographic Scope: Global

Clinical Area: Hemophilia

Link to full RFP: 2019 Global Hemophilia ASPIRE

Application Due Date: August 31, 2019

Specific Area of Interest:Projects that will be considered for Pfizer support will focus on the following areas in Gene Therapy for Hemophilia A or B:

1. Basic Science of Gene Therapy for Hemophilia

  • Basic science, tropism, transduction efficiency & tolerability of Adeno associated virus (AAV)
  • AAV antibody Titer assessment, reduction, tolerance
  • Role of immunosuppression in managing transaminitis

2. Basic Science of TFPI & Anti-TFPI Monoclonal Antibodies

  • Basic biology of TFPI interactions with Protein C, ATIII, & Protein S
  • Cross talk among regulators (e.g., Protein S being a co-factor for both Protein C and TFPI)
  • Role of different TFPI pools in regulation of coagulation
  • Pharmacology resulting from concomitant treatments (especially antifibrinolytics) added to anti-TFPI

3. Patients with MILD Hemophilia A or B

  • Natural history of mild Hemophilia
  • Arthropathy: presence, development, clinical burden and joint damage in mild Hemophilia
  • Quality of Life/Work analysis and cost of care in mild Hemophilia
  • Development and validation of Patient Reported Outcomes (PRO) instruments in Hemophilia

Membership Management Software Powered by YourMembership  ::  Legal